“In the Know” features conversations with the people and personalities in biopharma.

Azita Saleki-Gerhardt is used to simultaneously navigating divergent cultures. At the University of Wisconsin, she slowly adapted to American life while struggling to dispel her fellow students’ stereotypes about Iran, her home country. After earning a doctorate in pharmaceutics, she spent the 1990s as a scientist developing and tweaking drug formulas in Abbott’s labs, and later overseeing technical aspects of the company’s manufacturing process.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Here are the cardinal rules for scientists presenting to CEO’s:

    1) CEOs are optimists by nature.
    2) their mind is 95% made up before you enter the room.
    3) your job is to “close the deal”.
    4) forget about fair and balanced.
    5) the probability of success is always 95%.

    You may as well be optimistic since it’s your neck that will be first on the chopping block when your studies fail.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy